ImmuPharma has confirmed that the last patient has completed dosing within the 52-week, randomised, double-blinded, phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.
It said that 200 patients had been successfully recruited and randomised and top line results remained on track to be reported in Q1 2018.
Chairman Tim McCarthy said: 'We are delighted to announce this significant milestone that all patients have now completed dosing in this pivotal Phase III trial for Lupuzor.
'Importantly we continue to see robust safety and we look forward with continued confidence to reporting top line results of the study in Q1 2018.'
At 8:06am: (LON:IMM) ImmuPharma PLC share price was +9.38p at 162.38p